Use of Big Data to Assess Dyslipidemia Management in Greece: Real-World Insights From the National Healthcare Payer
Author(s)
Panos Stafylas, MD, MSc, PhD1, PANAGIOTA LITSA, MSc, PharmD2, PANAGIOTA LYMPEROPOULOU, MD2, Christina Georgi, BSc, MSc, PhD2, Nandia Gogozotou, MBA, MSc, PharmD, PhD2.
1HealThink, Thessaloniki, Greece, 2National Organization for Healthcare Services Provision (EOPYY), Athens, Greece.
1HealThink, Thessaloniki, Greece, 2National Organization for Healthcare Services Provision (EOPYY), Athens, Greece.
OBJECTIVES: Dyslipidemia is a major modifiable risk factor for cardiovascular disease (CVD), the leading cause of death in Greece, affecting nearly half of the adult population. Although lipid-lowering therapies (LLTs) are widely prescribed, their cost-effectiveness is challenged by suboptimal treatment intensity and low rates of LDL-C target attainment. The objective of this study was to analyze nationwide real-world data to evaluate treatment patterns, therapeutic intensity, and potential inefficiencies in dyslipidemia management from the perspective of the national healthcare payer and provider, the National Organisation for the Provision of Health Services (EOPYY), in 2024.
METHODS: Anonymized claims and prescription data were retrieved from the national e-prescription systems (K.M.E.S. & eDAPY), covering over 99% of the population. Adults with a diagnosis of dyslipidemia (ICD-10: E78) or at least one LLT prescription (ATC: C10) in 2024 were included. Utilization was analyzed at the ATC-4 and ATC-5 levels, focusing on treatment intensity (high- vs. moderate-intensity statins), monotherapy vs. combination therapy, and associated costs.
RESULTS: In 2024, 2,545,626 patients were diagnosed with dyslipidemia, and 2,533,046 received LLTs, representing 28.8% of the Greek adult population. Statins (C10AA) dominated usage (18.45 million packs), followed by statin-ezetimibe combinations (5.9 million), ezetimibe, and fibrates. Only 19% of patients received high-intensity statins (atorvastatin 40 mg and rosuvastatin 20 and 40 mg), while 25% were treated with statin-ezetimibe combinations. The estimated average population-level adherence to LLTs was 73%. The total direct expenditure by EOPYY for LLTs reached €264 million, with 43.4% attributed to fixed ezetimibe-statin combinations.
CONCLUSIONS: Compared to the EMENO nationwide survey (14.1% treated in 2013-2016), LLT uptake has nearly doubled. Despite widespread prescription of LLTs, high-intensity regimens remain underutilized. These findings highlight persistent therapeutic inertia and the need for targeted interventions to enhance guideline adherence, optimize resource allocation, and improve cardiovascular outcomes in Greece.
METHODS: Anonymized claims and prescription data were retrieved from the national e-prescription systems (K.M.E.S. & eDAPY), covering over 99% of the population. Adults with a diagnosis of dyslipidemia (ICD-10: E78) or at least one LLT prescription (ATC: C10) in 2024 were included. Utilization was analyzed at the ATC-4 and ATC-5 levels, focusing on treatment intensity (high- vs. moderate-intensity statins), monotherapy vs. combination therapy, and associated costs.
RESULTS: In 2024, 2,545,626 patients were diagnosed with dyslipidemia, and 2,533,046 received LLTs, representing 28.8% of the Greek adult population. Statins (C10AA) dominated usage (18.45 million packs), followed by statin-ezetimibe combinations (5.9 million), ezetimibe, and fibrates. Only 19% of patients received high-intensity statins (atorvastatin 40 mg and rosuvastatin 20 and 40 mg), while 25% were treated with statin-ezetimibe combinations. The estimated average population-level adherence to LLTs was 73%. The total direct expenditure by EOPYY for LLTs reached €264 million, with 43.4% attributed to fixed ezetimibe-statin combinations.
CONCLUSIONS: Compared to the EMENO nationwide survey (14.1% treated in 2013-2016), LLT uptake has nearly doubled. Despite widespread prescription of LLTs, high-intensity regimens remain underutilized. These findings highlight persistent therapeutic inertia and the need for targeted interventions to enhance guideline adherence, optimize resource allocation, and improve cardiovascular outcomes in Greece.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
RWD189
Topic
Health Service Delivery & Process of Care, Organizational Practices, Real World Data & Information Systems
Topic Subcategory
Health & Insurance Records Systems
Disease
Cardiovascular Disorders (including MI, Stroke, Circulatory), Diabetes/Endocrine/Metabolic Disorders (including obesity), Generics, No Additional Disease & Conditions/Specialized Treatment Areas